Remarkably, in vivo experiments using athymic nu-/nu- mice implanted with subcutaneous HeLa tumors demonstrated that systemic MMPi treatment resulted in the reduction of MICA serum levels and a concomitant augmentation of MICA expression on cancer cells reinforcing the immune cell therapy mediated by cytokine-induced killer cells (132). The gene discussed is MICA; the disease is cancer.